Osteoarthritis and crystal arthropathies

15 Osteoarthritis and crystal arthropathies



Cases relevant to this chapter


16, 68, 70–71, 76, 86, 92



Essential facts




1. Osteoarthritis (OA) is the clinical and pathological outcome of a range of factors that lead to pain, disability and structural failure in synovial joints.


2. By the age of 65 years, 80% of people have radiographic evidence of OA affecting the spine, hips, knees, hands and feet, but only one in four are symptomatic.


3. OA is a dynamic process of remodelling and proliferation of new bone, cartilage and connective tissues, as well as focal degeneration of articular cartilage.


4. Insidious pain occurs as a result of increased pressure or microfractures in the subchondral bone, low-grade synovitis, inflammatory effusions, capsular distension, enthesitis or muscle spasm, and nocturnal aching may be associated with hyperaemia in the subchondral bone.


5. Consider a predisposing underlying condition in patients with OA before the age of 40 years or if OA develops in unusual sites.


6. Medical treatment of OA is to relieve symptoms, maintain and improve joint function, and minimize disability and handicap; optimal management requires a combination of non-pharmacological and pharmacological modalities.


7. Surgical management of OA is indicated where medical therapy has failed; joint replacement is effective and cost-effective, irrespective of age.


8. Calcium pyrophosphate dihydrate crystals are deposited at entheses, in hyaline cartilage and in fibrocartilage, and are associated with chondrocalcinosis and degenerative changes; shedding of crystals into joints can provoke acute synovitis (pseudogout) or chronic pyrophosphate arthropathy.


9. Acute gout usually presents as monoarthritis in a distal joint of the foot or hand.


10. Recurrent attacks of gout cause progressive cartilage and bone erosion, deposition of palpable masses of urate crystals (‘tophi’), and an asymmetrical erosive inflammatory polyarthritis. Gout is now the commonest type of chronic inflammatory arthritis.



Osteoarthritis


Osteoarthritis (OA), also sometimes called osteoarthrosis or degenerative joint disease, is not a single disease, but rather the clinical and pathological outcome of a range of disorders and conditions that lead to pain, disability and structural failure in synovial joints. OA is classified as being primary (idiopathic) or secondary, when it follows some clearly defined predisposing disorder or disease (Table 15.1), but the development of all types of OA is associated with multiple aetiological factors.




Epidemiology


OA is the commonest type of arthritis. Radiographic and autopsy surveys show a steady age-related increase in prevalence from the age of 30 years. By the age of 65 years, 80% of people have some radiographic evidence of OA, although only one in four is symptomatic. The joints most frequently affected are the spine, hips, knees, and some of the small joints of the hands and feet (Fig. 15.1). Community-based studies in the UK have shown that 10% of the population over the age of 55 years have troublesome knee pain and, of those, 25% are severely disabled. OA is the leading cause of physical disability in people age over 65 years. The prevalence of both radiographically defined OA and OA-related disability is greater in women than in men. Although disability associated with OA also increases steadily with age, the majority of people with OA-related disability in the community are between the ages of 55 and 75 years.



Risk factors for OA include constitutional factors such as age, sex, the shape and alignment of joints, obesity and some genetic determinants, but there are also important environmental triggers, such as previous injury or the repetitive trauma associated with certain recreational activities, such as weightlifting or long-distance running, and with some occupations, such as mining and farming. Mechanical factors play a role in the pathogenesis of all types of primary, as well as secondary, OA. Joint failure occurs when mechanical stresses overwhelm the capacity of articular tissues to resist and repair the damage. Structural failure of the articular cartilage, bone and periarticular tissues can result from abnormal mechanical stresses damaging previously normal tissues, or from the failure of pathologically impaired joint tissues in response to physiologically normal mechanical forces (Fig. 15.2). Obesity, joint mal-alignment, occupational trauma and muscle weakness are all important, potentially modifiable, biomechanical risk factors that determine the site and severity of the disease. Race and ethnicity have some influence on the probability of developing OA at different sites. Although OA of the knee is prevalent in all ethnic groups (particularly frequent in black women), hip, hand and generalized OA are seen predominantly in Caucasians. Genetic factors are known to be important determinants. Twin studies suggest heritability of up to 65% in primary OA of the hand and knee, but the susceptibility genes themselves still remain largely undefined.



Progress has been made in identifying mutations in collagen genes that are associated with different types of bone and cartilage dysplasia where OA is part of a more complex phenotype, but none of these single gene mutations in genes that code for structural matrix proteins appears to be important in determining susceptibility to the common types of OA. Recently, however, there has been some progress in identifying a promoter polymorphism in a bone morphogenetic protein (growth differentiation factor 5) that is associated with both hip and knee OA, as well as other polymorphisms in genes that code for signalling proteins involved in the development and maintenance of articular cartilage, which appear to be associated with susceptibility to hip OA in certain ethnic groups (see Chapter 3).



Pathology and pathogenesis


OA involves all tissues of the joint (subchondral bone, ligaments, capsule and synovial membrane) as well as the articular cartilage, but inflammatory changes in the synovium are usually minor and secondary. To a variable extent OA is a dynamic process characterized by remodelling of the anatomy of the joint and proliferation of new bone in the form of osteophytes, as well as by focal degeneration of articular cartilage. In many cases these processes reach a state of non-progressive equilibrium, but in others there is symptomatic failure of the joint characterized by progressive degeneration of the articular cartilage with fibrillation, fissuring, ulceration and, eventually, full-thickness focal loss of cartilage at sites of joint loading. In addition, with wear, there is compaction and sclerosis (‘eburnation’) of the adjacent subchondral bone and the formation of bone cysts (Fig. 15.3). The biomechanical properties of the cortical and subchondral bone play an important role in protecting articular cartilage following impact loading. It is suggested that the pathogenesis of OA in some cases may be initiated by an increase in the density and stiffness of the subchondral bone following the healing of microfractures caused by unprotected loading of joints. The consequent loss of bone viscoelasticity results in steep stiffness gradients in the bone. This in turn results in stretching and fibrillation of the overlying articular cartilage, as well as focal osteonecrosis and the formation of bone cysts. In support of this hypothesis, patients with hip and knee OA have higher than normal bone mass and there is evidence that focal increases in subchondral bone density can precede and predict future cartilage loss in patients with OA of the knee. The sequence of pathological and biochemical changes in the articular cartilage in OA follows a characteristic pattern (Table 15.2), whether primary or secondary to changes in the subchondral bone. Early increases in matrix hydration and articular cartilage thickness follow disruption of the collagen fibre network, loss of tensile strength in the superficial zone of the articular cartilage and swelling of the negatively charged, high-molecular-weight proteoglycan, aggrecan. Initially, chondrocyte activation and proliferation of clusters of chondrocytes are associated with an anabolic response with increased synthesis and turnover of matrix collagens and proteoglycans, but in the later stages of OA, catabolism of cartilage matrix proteins outstrips the capacity for cartilage repair. Anabolic mediators include growth factors, such as the insulin-like growth factor (IGF-1), fibroblast growth factor (FGF), transforming growth factor β (TGFβ) and the bone morphogenetic proteins (BMPs): the anti-inflammatory cytokine interleukin (IL)-4 and proteinase inhibitors, such as tissue inhibitors of metalloproteinases (TIMPs) and plasminogen activator inhibitor (PAI). Catabolic mediators include nitric oxide, prostaglandins and the pro-inflammatory cytokines IL-1β, tumour necrosis factor (TNFα), IL-6 and IL-17, as well as metalloproteinases (MMP-1, -8, and -13) and aggrecanases (ADAM-TS-4 and -5).





Clinical features


Pain is the presenting symptom in the majority of patients. Usually insidious in onset and intermittent at first, the pain is typically aching in character. Initially, it is provoked by weight-bearing or movement of the joint, and relieved by rest, but as the disease progresses the pain may be more prolonged and experienced at rest, and may become severe enough to wake the patient at night. Prolonged early morning stiffness is not a feature as it is in rheumatoid arthritis and other predominantly inflammatory joint diseases, but a few minutes of early morning stiffness and transient stiffness (gelling) after rest are common. Pain in OA can emanate from all the tissues of the joint, except the articular cartilage, which is aneural. Pain may result from increased pressure or microfractures in the subchondral bone, from low-grade synovitis, inflammatory effusions, capsular distension, enthesitis or muscle spasm, and nocturnal aching may be associated with hyperaemia in the subchondral bone. Associated anxiety and depression are not uncommon, and these can amplify pain and disability. There is only a weak relationship between symptoms and radiographic evidence of structural changes of OA at all joint sites, although the correlation between pain and structural changes is somewhat stronger in the weight-bearing joints (hip > knee) than in the small joints of the hands. Patients may develop painless functional impairment due to restricted movement in the hands, hips or knees. Physical signs associated with OA include: restriction of movement of joints as a result of capsular fibrosis or blocking by osteophytes, palpable bony swelling, periarticular or joint-line tenderness, deformities with or without joint instability, muscle weakness and wasting in addition to occasional joint effusions, and palpable or even audible joint crepitus.



Common clinical presentations


The salient features of the common types of hip, knee, hand and nodal generalized OA are summarized in Table 15.3.


Table 15.3 Common clinical types/patterns of osteoarthritis



























Knee Osteoarthritis Hip Osteoarthritis Hand Osteoarthritis
Patello-femoral and medial joint compartments Supero-lateral or central (medial or polar) Distal interphalangeal and proximal interphalangeal joints, carpometacarpal (CMC) joints of the thumbs
Knee pain
Pain on walking
↑uneven ground
↑stairs
Antalgic gait
Difficulty rising from chairs
Groin pain
→ thigh/medial side of the knee
→ buttock
Antalgic gait
Difficulty with socks and toenails
Pain/swelling/stiffness +
Restricted movements
Symptoms often settle
Hand function preserved
Frequent family history
Bilateral > unilateral Unilateral > bilateral Usually bilateral
Women > men Women > men Women > men
Perimenopausal onset
Varus > valgus or
Fixed flexion deformities
Joint-line tenderness
Joint-line bony swelling
Crepitus
Quads muscle wasting
Pain/restricted movements: internal rotation (early), external rotation/abduction (later)
Fixed flexion/ext. rotation
Limb shortening
Quads/gluteal muscle weakness and/or wasting
Heberden nodes ± Bouchard nodes
Subluxation 1st CMC
Squaring of hand
Associated with OA in other joints (especially knees and medial OA of the hips)

Hip OA commonly affects the superior pole of the joint. Typically, patients present with pain in the groin on exercise, but referred pain in the buttock, anterior thigh, knee and even the lower leg are not uncommon. With increasing severity it radiates down to the knee, is constant on exercise, and begins to cause stiffness and inability to reach down to tie shoe-laces. Pain begins to disturb sleep. Enjoyment of active hobbies is curtailed, and progression to joint destruction and fixed flexion contracture can be the end result in some patients. Characteristically, examination reveals an antalgic gait with painful restriction of internal rotation with the hip in flexion. Medial pole OA is less common. It occurs more frequently in women, is more frequently bilateral, and less frequently progresses. In patients with generalized nodal OA, the pattern of hip involvement is usually also medial or concentric. Bony destruction of the acetabulum or femoral head may lead to a ‘bobbing’ short-leg gait. A Trendelenburg gait is rare, but a coxalgic (Duchenne) gait is more common due to a desire to off-load the hip abductor muscles and hence reduce the joint reaction force, which is often three times body weight in single-leg stance. There is little to see apart from thigh wasting and, perhaps, fixed flexion. Tenderness is rare. Range of movement reveals a global deficit and fixed flexion; reduced adduction and internal rotation are often seen. Rotation is often the most ‘irritable’ of the movements.


Antero-posterior radiographs of the hip and pelvis should be inspected carefully to detect cardinal features of OA. Destructive arthropathy and avascular necrosis may be associated with non-steroidal anti-inflammatory drug (NSAID) therapy.


Knee OA commonly affects the medial and patello-femoral compartments of the joint, but may affect any of the three compartments. The medial compartment is most frequently affected, and leads to a varus deformity. Forces that occur on weight-bearing will pass medial to the knee and this increases point-loading in the medial compartment. Typically, patients present with anterior or medial knee pain aggravated by walking on uneven ground and by ascending or descending stairs. On examination they frequently have a characteristic antalgic gait and bilateral, symmetrical varus deformities. In some patients, knee OA is associated with generalized nodal OA. Unilateral knee OA, especially in men, may be a consequence of a previous injury, meniscus tear or complete meniscal resection.


Nodal OA is a clinically distinct form of primary generalized OA, with a strong genetic component. It is much more common in women than in men and characteristically affects the interphalangeal (IP) joints of the fingers (DIPJs > PIPJs) and the carpometacarpal joints of the thumbs. The onset, which is sometimes subacute with considerable pain, swelling and local inflammation, is often in the perimenopausal period, and may be triggered by oestrogen withdrawal and other endocrine changes at this time. Although multiple joints in both hands are frequently affected, the onset is typically episodic and additive in pattern, with each joint going through a sequence of changes over a number of months. Pain, soft-tissue swelling and tenderness are followed by the gradual development of hard, bony swellings on either side of the extensor tendons on the dorsal aspect of the fingers in relationship to the IP joints. Heberden nodes at the DIPJs are more frequent than Bouchard nodes at the PIPJs. Once the inflammation has settled, patients are left with relatively pain-free, knobbly fingers. Although the lesions can be associated with considerable deformity and subluxation, serious disability is unusual. In generalized nodal OA, osteophyte formation and subluxation of the first carpometacarpal joints results in characteristic ‘squaring’ of the hands, and the knees and other joints may be also affected. Rarely, in cases with a more acute onset (‘hot Heberden nodes’), the initial soft-tissue inflammation is associated with the development of cysts containing hyaluronate. Erosive OA is the name sometimes given to describe a rarer variant of nodal osteoarthritis, which is characterized by similar episodic symptoms and signs of local inflammation followed by the development of more destructive subchondral erosions associated with florid proliferation of bone, instability, and subluxation in the PIPJs and DIPJs.



Atypical and ‘secondary’ osteoarthritis


The possibility of some defined predisposing underlying condition (see Table 15.1) needs to be considered, particularly in patients who develop typical symptoms and signs of OA before the age of 40 years, in those who develop OA in joints that are usually not affected, and in those with certain characteristic patterns of joint involvement. A history of major preceding trauma, such as a fracture that resulted in articular cartilage damage or subsequent mal-alignment, is often found to be the cause of monoarticular OA developing at an early age or in a joint, such as the ankle, that is seldom otherwise affected. Nearly 50% of patients have knee OA 21 years after open meniscectomy, and the average time to develop hip OA following a fracture dislocation is 7 years. Early-onset OA with prominent involvement of the second and third metacarpophalangeal (MCP) joints is very characteristic in patients with haemochromatosis and may be an early clinical clue that leads to establishment of the diagnosis (for more details see Chapter 14). Although deposition of calcium pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP or apatite) crystals is common in articular cartilage in OA, the possibility of familial CPPD disease should be considered in patients presenting with premature knee OA. This is especially important when the knee OA is accompanied by frequent inflammatory episodes or prominent hypertrophic radiographic features, and in patients presenting with OA in relatively atypical joints, such as the shoulder, elbow or radiocarpal joints in the wrists.



Investigations


Plain radiographs are used to assess the severity of the structural changes in patients with OA. Because radiographic evidence of OA is so frequent in asymptomatic middle-aged and elderly persons, it is important to consider the clinical features (symptoms and signs) when interpreting the results. Focal, rather than uniform, joint space narrowing and the presence of osteophytes are the main radiographic features, with subchondral bone sclerosis and cysts in more advanced cases. Ossified synovial loose bodies and chondrocalcinosis can also sometimes be detected on plain radiography. Standing radiographs are required to assess the extent to which joint space narrowing reflects loss of articular cartilage in the tibio-femoral joints.


Magnetic resonance imaging (MRI) is being developed for the earlier and more quantitative detection of articular cartilage changes, including changes in hydration and proteoglycan composition, but has yet to be refined and validated sufficiently to make it useful in clinical practice. This is also true of isotope scans with 99Tc-labelled bisphosphonate, which in research studies have shown increased uptake of isotope in OA joints that subsequently go on to develop progressive structural changes. MRI is, however, useful for detecting intra-articular soft-tissue lesions, such as meniscus tears, and for the diagnosis of osteonecrosis. Bone scintigraphy is occasionally used for the detection of osteonecrosis, stress fractures and bone metastases but is increasingly being replaced by MRI.


Blood tests are not helpful in the diagnosis or management of OA and are used largely to exclude other diseases associated with systemic inflammation or metabolic abnormalities. For example, measurements of serum calcium and alkaline phosphatase are critical for the diagnosis of primary hyperparathyroidism and hypophosphatasia; measurement of serum ferritin is required for the diagnosis of haemochromatosis; and detection of homogentisic acid in the urine will confirm a diagnosis of ochronosis.


Although cartilage degradation products, such as hyaluronan, keratan sulphate and cartilage oligomeric protein, and cartilage synthesis markers, such as Type II collagen c-pro-peptide, have been shown to be increased in the plasma, synovial fluid or urine of patients with OA, there are currently no biochemical or molecular markers that have clinical utility for diagnosis, monitoring the progress of structural changes, or assessing the prognosis of OA in clinical practice.


Synovial fluid analysis in OA is really indicated only to exclude bacterial joint infection or gout. The fluid is usually clear and viscous with a low cell count. Detection of crystals by polarizing light microscopy is not helpful in distinguishing OA from primary calcium crystal deposition disorders, because crystals of CPPD and BCP are each detected in up to half of all effusions from patients with knee OA.



Management


Treatment is directed predominantly at relieving symptoms, maintaining and improving joint function, and minimizing disability and handicap. Optimal management of patients with all types of OA requires a combination of non-pharmacological and pharmacological modalities.



Non-pharmacological modalities of therapy




• All patients should be provided with information and education about the objectives of treatment and the importance of changes in lifestyle, exercise, weight reduction, and other measures to unload the damaged joint. The initial focus should be on self-help and patient-driven treatments, rather than on passive therapies delivered by health professionals.


• All patients with lower-limb OA should be given advice about appropriate footwear with thick, soft soles. Laterally wedged insoles can give symptomatic relief to some patients with medial tibio-femoral compartment knee OA.


• Patients with symptomatic OA of the hip or knee can benefit from referral to a physiotherapist for: (a) assessment and instruction in appropriate exercises to reduce pain and improve functional capacity, and (b) assessment and provision and instruction in the use of a stick or walker in appropriate circumstances.


• Patients with hip and knee OA should be encouraged to undertake and continue with regular aerobic, muscle-strengthening and range-of-movement exercises. Pool exercises can be effective in patients with symptomatic hip OA associated with muscle spasm.


• Patellar taping can provide short-term symptom relief in some patients with patello-femoral OA.


• A knee brace can reduce pain, improve stability and reduce the risk of falls in patients with knee OA associated with mild/moderate varus or vagus instability.


• Heat packs, ice packs, acupuncture and transcutaneous electrical nerve stimulation have all been shown to be effective for helping with short-term pain control in some patients with knee OA in controlled trials.



Pharmacological modalities of therapy




• Paracetamol (up to 3 g daily) should be the analgesic of first choice for patients with symptomatic OA.


• In patients who do not respond adequately to a trial of paracetamol, the choice of alternative or additional analgesics needs to take into account both the relative efficacy and safety of the drug or drug combination being considered as well as concomitant medication and co-morbidities.


• In some patients who do not respond adequately to paracetamol, NSAIDs at the lowest effective doses can be added or substituted, but long-term use of NSAIDs should be avoided if possible. In patients with increased gastrointestinal risk, a cyclo-oxygenase (COX) 2 selective agent or a non-selective NSAID with co-prescription of a proton pump inhibitor or misoprostol for gastroprotection can be considered.


• All NSAIDs (including COX2-selective agents) should be used with caution in patients with cardiovascular risk factors.


• Topical NSAIDs or topical capsaicin can be effective as adjuncts or alternatives to oral analgesics in some patients with symptomatic knee OA.


• Intra-articular injections with corticosteroids can be considered in patients with moderate to severe pain who are not responding adequately to oral analgesic/anti-inflammatory agents, and in patients with symptomatic knee OA with effusions or other physical signs of local inflammation.


• Intra-articular injections of hyaluronate can be helpful in some patients with knee OA who are unresponsive to, or intolerant of, repeated injections of intra-articular corticosteroids.


• Treatment with glucosamine and/or chondroitin sulphate may provide symptomatic benefit in patients with knee OA. If no response is apparent within 6 months, treatment should be discontinued. The evidence that these agents may also have structure-modifying effects in slowing the progression of articular cartilage loss remains inconclusive.


• The use of opioids and narcotic analgesics can be considered in exceptional circumstances for the treatment of severe, refractory pain where other pharmacological agents have been ineffective or are contraindicated. Non-pharmacological therapies should be continued in such patients and surgical treatments should be considered.

< div class='tao-gold-member'>

Stay updated, free articles. Join our Telegram channel

Jul 12, 2016 | Posted by in RHEUMATOLOGY | Comments Off on Osteoarthritis and crystal arthropathies

Full access? Get Clinical Tree

Get Clinical Tree app for offline access